According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Only one in every six million people have the Rh null blood type. Now researchers are trying to grow it in the laboratory in ...

A U.S. biological research institute has developed a new genetic modification technique that promises a wide range of organism mutations while being safer than the ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...

In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and ...

In a 15-patient, Phase 1 one, first-in-human trial, a one-time, CRISPR-Cas9 gene-editing therapy safely reduced LDL ...

With a snip of a gene, doctors may one day permanently lower dangerously high cholesterol, possibly removing the need for ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...

CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and fat storage. Preclinical studies showed strong metabolic benefits, ...